Core Viewpoint - A class action lawsuit has been filed against MoonLake Immunotherapeutics, alleging that the company misled investors regarding the efficacy of its drug candidate SLK, particularly in comparison to the FDA-approved drug BIMZELX [1][2]. Allegations - The lawsuit claims that during the class period, MoonLake failed to disclose critical information about the differences between its Nanobody drug SLK and traditional monoclonal antibodies, including: - Both SLK and BIMZELX target the same inflammatory cytokines IL-17A and IL-17F [2]. - SLK's Nanobody structure does not provide a clinical benefit over BIMZELX's monoclonal structure [2]. - The supposed increased tissue penetration of SLK does not translate to improved clinical efficacy [2]. - Consequently, the positive statements made by the company regarding SLK's superiority lacked a reasonable basis [2]. Stock Price Impact - Following the announcement of the Phase 3 VELA program results on September 28, 2025, which indicated that SLK did not demonstrate competitive efficacy against BIMZELX, MoonLake's stock price plummeted by $55.75 per share, or 89.9%, closing at $6.24 on September 29, 2025 [3]. Next Steps for Investors - Shareholders interested in participating in the class action must submit their papers to the court by December 15, 2025, to serve as lead plaintiff, representing other class members in the litigation [4]. - Investors can remain absent class members and still be eligible for recovery without taking any action [4]. Company Background - Robbins LLP, the firm leading the class action, has been focused on shareholder rights litigation since 2002, aiming to help shareholders recover losses and improve corporate governance [5].

Core Viewpoint - MoonLake Immunotherapeutics faces a securities class action lawsuit following the announcement of disappointing Phase 3 trial results for its product candidate sonelokimab (SLK), leading to a significant drop in share price by approximately 90% [1][2][6]. Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on treating skin inflammatory diseases, specifically targeting cytokines IL-17A and IL-17F [3][4]. Legal Proceedings - A class action lawsuit has been filed against MoonLake, alleging that the company misled investors regarding the trial design and efficacy data of SLK prior to the announcement of the trial results [1][2][3]. - The class period for the lawsuit is from March 10, 2024, to September 29, 2025, with a lead plaintiff deadline set for December 15, 2025 [3]. Trial Results and Market Reaction - The Phase 3 trial results revealed that only one of the two trials achieved statistical significance, with the efficacy being substantially lower than that of a competitor's product, BIMZELX [6]. - Following the announcement, MoonLake's share price plummeted by $55.75, representing a 90% decrease, which analysts described as a "worst case outcome" [2][6]. Product Comparison - SLK's commercial prospects were heavily reliant on demonstrating efficacy comparable to or superior to BIMZELX, which is already FDA-approved for the same indication [4]. - The lawsuit claims that MoonLake made false statements regarding the advantages of SLK's Nanobody structure over traditional monoclonal antibodies, asserting that it would lead to superior clinical benefits [5]. Investor Communication - Throughout the class period, MoonLake promoted SLK's structural advantages, claiming it could achieve benefits unattainable by monoclonal antibodies and positioned it as a potential "gold standard" treatment [5]. - The lawsuit alleges that these statements were misleading and that the company failed to disclose critical information about SLK's clinical efficacy [5][6].

SAN DIEGO, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that the MoonLake class action lawsuit – captioned Bridgewood v. MoonLake Immunotherapeutics, No. 25-cv-08500 (S.D.N.Y.) – seeks to represent purchasers or acquirers of MoonLake Immunotherapeutics (NASDAQ: MLTX) common stock and charges MoonLake and certain of MoonLake’s top executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the Moo ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In MoonLake (MLTX) To Contact Him Directly To Discuss Their Options If you purchased or acquired MoonLake Immunotherapeutics common stock between March 10, 2024 through September 29, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Oct. 15, 2025 (GLOBE NEWSWIR ...

BOSTON, Oct. 15, 2025 (GLOBE NEWSWIRE) -- On behalf of an individual investor, Block & Leviton LLP filed a class action lawsuit today against MoonLake Immunotherapeutics (Nasdaq: MLTX), along with certain individuals, alleging that they violated federal securities laws by issuing false and misleading statements concerning the company’s business, operations, and prospects. A copy of the Complaint is available on Block & Leviton’s website. The suit alleges that MoonLake Immunotherapeutics misled investors abo ...